Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harter

Showing results (981-990 of 1,729) with videos related to

Pageof 173
Sort By:
Journal of the American Academy of Dermatology|November 17, 2024
Clinical presentations and decreasing incidence of melanoma in pediatric and adolescent and young adult patients: 76,108 cases from a nationally representative cohortBianca E Ituarte, Mitchell A Taylor, Sierra I Thomas, et al.
Neoplasia (New York, N.Y.)|February 27, 2013
MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patientsKai Doberstein, Nico Steinmeyer, Ann-Kathrin Hartmetz, et al.
Neurosurgery|April 5, 2018
Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type GlioblastomasFlorian Gessler, Joshua D Bernstock, Anne Braczynski, et al.
Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society|November 10, 2007
Fraser syndrome: affected siblings born to nonconsanguineous parents and diagnosed at autopsyAnn De Jong, Miranda Warren, William Rehrauer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 5, 2009
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR GermanyJacobus Pfisterer, Andreas Du Bois, Eva-Katrin Bentz, et al.
European Urology|September 2, 2020
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological ResponsesChristian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
Frontiers in Plant Science|May 6, 2024
OneFlowTraX: a user-friendly software for super-resolution analysis of single-molecule dynamics and nanoscale organizationLeander Rohr, Alexandra Ehinger, Luiselotte Rausch, et al.
Preventive Medicine|October 23, 2022
Body image distortion among Brazilian and Portuguese women with children: A comparative study between the ELSA-Brasil and Generation XXI cohortsAna Luísa Patrão, Maria da Conceição Almeida, Ana Henriques, et al.
Archives of Gynecology and Obstetrics|May 21, 2015
Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancerChristina Fotopoulou, Ahmed El-Balat, Andreas du Bois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 11, 2005
Non-enrolment of ovarian cancer patients in clinical trials: reasons and backgroundP Harter, A du Bois, C Schade-Brittinger, et al.
Pageof 173

Showing results (981-990 of 1,729) with videos related to

Sort By:
Pageof 173
Journal of the American Academy of Dermatology|November 17, 2024
Clinical presentations and decreasing incidence of melanoma in pediatric and adolescent and young adult patients: 76,108 cases from a nationally representative cohortBianca E Ituarte, Mitchell A Taylor, Sierra I Thomas, et al.
Neoplasia (New York, N.Y.)|February 27, 2013
MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patientsKai Doberstein, Nico Steinmeyer, Ann-Kathrin Hartmetz, et al.
Neurosurgery|April 5, 2018
Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type GlioblastomasFlorian Gessler, Joshua D Bernstock, Anne Braczynski, et al.
Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society|November 10, 2007
Fraser syndrome: affected siblings born to nonconsanguineous parents and diagnosed at autopsyAnn De Jong, Miranda Warren, William Rehrauer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 5, 2009
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR GermanyJacobus Pfisterer, Andreas Du Bois, Eva-Katrin Bentz, et al.
European Urology|September 2, 2020
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological ResponsesChristian Pfister, Gwenaelle Gravis, Aude Fléchon, et al.
Frontiers in Plant Science|May 6, 2024
OneFlowTraX: a user-friendly software for super-resolution analysis of single-molecule dynamics and nanoscale organizationLeander Rohr, Alexandra Ehinger, Luiselotte Rausch, et al.
Preventive Medicine|October 23, 2022
Body image distortion among Brazilian and Portuguese women with children: A comparative study between the ELSA-Brasil and Generation XXI cohortsAna Luísa Patrão, Maria da Conceição Almeida, Ana Henriques, et al.
Archives of Gynecology and Obstetrics|May 21, 2015
Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancerChristina Fotopoulou, Ahmed El-Balat, Andreas du Bois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 11, 2005
Non-enrolment of ovarian cancer patients in clinical trials: reasons and backgroundP Harter, A du Bois, C Schade-Brittinger, et al.
Pageof 173